GlaxoSmithKline (GSK)’s B7-H3-targeted antibody-drug conjugate (ADC), GSK’227 has gained priority medicines (PRIME) ...

▎药明康德内容团队编辑Actuate Therapeutics今日公布其在研GSK-3β小分子抑制剂elraglusib联合吉西他滨/白蛋白紫杉醇（GnP），用于转移性胰腺导管腺癌（mPDAC）一线治疗2期试验Actuate-1801 Part ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

GSK plc’s GSK HIV subsidiary, ViiV Healthcare announced that the Europe Medicines Agency’s (“EMA”) Committee for Medicinal ...

British drugmaker GSK said on Monday its experimental cancer drug Blenrep in combination with other treatments reduced the ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.

If approved by the FDA, Anzupgo would become the first treatment specifically indicated for CHE in the U.S. GSK previously ...

GSK last month announced that Blenrep had succeeded in improving overall survival in the trial, called DREAMM-7. The detailed ...

It was a busy week in the biotech sector with lots of regulatory and pipeline updates. Among bigwigs, Gilead Sciences, Inc.

London: GSK plc has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for ...

GSK (GSK) announced that the US Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, for ...